This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): hypoxia inducible factor-1 gene therapy, Ad2/HIF-1 alpha
Description: Hypoxia Inducible Factor-1 alpha, or HIF-1 alpha, is a transcription factor, or master gene, which has been shown to activate a cascade of proteins associated with blood vessel formation. This comprehensive approach contrasts with pro-angiogenic therapies that employ a single protein, such as VEGF isoform, given as a gene or as a recombinant protein. The Genzyme-engineered version of HIF-1 alpha turns on the expression of many angiogenic proteins - including VEGF isoforms, angiopoietins 2 and 4 and placenta growth factor among others.
Deal Structure: In October 2010, Sanofi-aventis announced it has commenced a tender offer for all outstanding shares of common stock of Genzyme for $69 per share, net to the seller in cash, without interest and less any required withholding taxes. In April 2011, Sanofi-aventis announced that it successfully completed its exchange offer for all outstanding shares of common stock of Genzyme Corporation.
Additional information available to subscribers only: